Bayer Sues Lupin Over Natazia Birth-Control Pill Patent

A unit of German drugmaker Bayer AG (BAYN) sued India’s Lupin Ltd. in federal court alleging infringement of a U.S. patent for the birth-control pill Natazia.

Bayer Pharma AG, based in Berlin, contends Mumbai-based Lupin is planning to offer a generic copy of Natazia in the U.S. before the patent expires in 2026, according to a complaint filed yesterday in Wilmington, Delaware.

Bayer said it’s entitled to triple damages if Lupin markets the drug in violation of patent-protection laws.

Natazia tablets have been approved by the U.S. Food & Drug Administration for use as an oral contraceptive and to treat pathologically heavy menstruation in women, according to the complaint.

“We do not comment on ongoing litigations as a matter of policy,” Lupin’s communications manager, Shamsher Gorawara, said today by e-mail.

The case is Bayer Pharma AG v. Lupin Ltd. (LPC), U.S. District Court, District of Delaware (Wilmington).

To see the patent, click: 8,071,577.

To contact the reporter on this story: Phil Milford at

To contact the editor responsible for this story: Michael Hytha at

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.